Humacyte, Inc. Ownership Filing Amendment

TL;DR

Humacyte (HUMA) ownership filing updated by major holders Niklason & Dougan. Watch for changes.

AI Summary

Laura E. Niklason and Brady W. Dougan have filed an amendment (Amendment No. 8) to their Schedule 13D for Humacyte, Inc., reporting changes as of August 29, 2024. The filing pertains to their ownership of Humacyte, Inc. common stock. The specific details of the changes in beneficial ownership are not fully detailed in the provided header information.

Why It Matters

This filing indicates potential shifts in significant shareholder positions, which could influence the stock's trading dynamics and future corporate strategy.

Risk Assessment

Risk Level: medium — Schedule 13D filings often signal significant changes in beneficial ownership, which can lead to increased volatility and strategic shifts for the company.

Key Players & Entities

• Humacyte, Inc. (company) — Subject Company
• Laura E. Niklason (person) — Filing Person
• Brady W. Dougan (person) — Filing Person
• Alpha Healthcare Acquisition Corp. (company) — Former Company Name

FAQ

Key Financial Figures

• $0.0001 — me of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $7.0922 — y members of Dr. Niklason at a price of $7.0922 per share for an aggregate sale price o
• $2,000,000 — n aggregate sale price of approximately $2,000,000. Said family members do not share the s
• $7.02 — n market at a weighted average price of $7.02 per share for an aggregate sale price o
• $538,000 — n aggregate sale price of approximately $538,000 (excluding commissions). On June 12, 2
• $7.30 — n market at a weighted average price of $7.30 per share for an aggregate sale price o
• $1,982,000 — n aggregate sale price of approximately $1,982,000 (excluding commissions). On August 27,
• $6.71 — n market at a weighted average price of $6.71 per share for an aggregate sale price o
• $1,696,000 — n aggregate sale price of approximately $1,696,000 (excluding commissions). On August 28,
• $6.47 — n market at a weighted average price of $6.47 per share for an aggregate sale price o
• $1,792,000 — n aggregate sale price of approximately $1,792,000 (excluding commissions). On August 29,
• $6.35 — n market at a weighted average price of $6.35 per share for an aggregate sale price o
• $2,236,000 — n aggregate sale price of approximately $2,236,000 (excluding commissions). On August 29,
• $6.545 — on Stock in the open market at price of $6.545 per share for an aggregate purchase pri
• $8,000 — gregate purchase price of approximately $8,000 (excluding commissions). Dr. Niklason u

Filing Documents

• humaschedule13d_a8.htm (SC 13D/A) — 90KB
• 0001818382-24-000173.txt ( ) — 92KB

Source and Amount of Funds or Other Consideration

Item 3. Source and Amount of Funds or Other Consideration

of the Schedule 13D is hereby amended to be supplemented by the following

Item 3 of the Schedule 13D is hereby amended to be supplemented by the following On June 11, 2024 Ayabudge sold 282,000 shares of Common Stock in a private transaction to a trust controlled by family members of Dr. Niklason at a price of $7.0922 per share for an aggregate sale price of approximately $2,000,000. Said family members do not share the same household as Dr. Niklason. On June 11, 2024 Ayabudge sold 76,630 shares of Common Stock in the open market at a weighted average price of $7.02 per share for an aggregate sale price of approximately $538,000 (excluding commissions). On June 12, 2024 Ayabudge sold 271,518 shares of Common Stock in the open market at a weighted average price of $7.30 per share for an aggregate sale price of approximately $1,982,000 (excluding commissions). On August 27, 2024 Ayabudge sold 252,676 shares of Common Stock in the open market at a weighted average price of $6.71 per share for an aggregate sale price of approximately $1,696,000 (excluding commissions). On August 28, 2024 Ayabudge sold 277,090 shares of Common Stock in the open market at a weighted average price of $6.47 per share for an aggregate sale price of approximately $1,792,000 (excluding commissions). On August 29, 2024 Ayabudge sold 352,112 shares of Common Stock in the open market at a weighted average price of $6.35 per share for an aggregate sale price of approximately $2,236,000 (excluding commissions). On August 29, 2024 Dr. Niklason purchased 1,222 shares of Common Stock in the open market at price of $6.545 per share for an aggregate purchase price of approximately $8,000 (excluding commissions). Dr. Niklason used personal funds for such acquisition. Mr. Dougan used the proceeds of the sales by Ayabudge to pay down leverage while providing a mechanism for the purchasers to acquire shares at a time that the Issuer was not conducting a financing transaction. Dr. Niklason is treated as indirectly beneficially owning the shares of Common Stock sold. Howeve

Interest in Securities of the Issuer

Item 5. Interest in Securities of the Issuer

of the Schedule 13D is hereby amended and restated in full as follows

Item 5 of the Schedule 13D is hereby amended and restated in full as follows (a)-(b) Number of shares of Common Stock beneficially owned Laura E. Niklason, M.D., Ph.D. 7,705,473 shares Brady W. Dougan 7,705,473 shares CUSIP No. 44486Q 103 Page 5 of 6 Pages Percent of class Laura E. Niklason, M.D., Ph.D. 6.3% Brady W. Dougan 6.3% The percentage ownership was calculated based upon 119,351,122 shares of the Issuer's Common Stock outstanding as of August 5, 2024, as reported in the Form 10-Q filed with the SEC on August 13, 2024 . Number of shares as to which such person has (i) Sole power to vote or to direct the vote Laura E. Niklason, M.D., Ph.D. 0 shares Brady W. Dougan 0 shares (ii) Shared power to vote or to direct the vote Laura E. Niklason, M.D., Ph.D. 7,705,473 shares Brady W. Dougan 7,705,473 shares (iii) Sole power to dispose or to direct the disposition of Laura E. Niklason, M.D., Ph.D. 0 shares Brady W. Dougan 0 shares (iv) Shared power to dispose or to direct the disposition of Laura E. Niklason, M.D., Ph.D. 7,705,473 shares Brady W. Dougan 7,705,473 shares (c) Except as reported in this Schedule 13D, none of the Reporting Persons has effected any transactions in the Common Stock during the past sixty (60) days. (d) Not applicable. (e) Not applicable. CUSIP No. 44486Q 103 Page 6 of 6 Pages SIGNATURE After reasonable inquiry and to the best of each of the undersigned's knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Date September 3, 2024 Laura E. Niklason By s Laura E. Niklason by Dale A. Sander as Attorney-in-Fact Date September 3, 2024 Brady W. Dougan By s Brady W. Dougan by Dale A. Sander as Attorney-in-Fact

View Full Filing

View this SC 13D/A filing on SEC EDGAR